PCI Biotech: Invitation to first-half year 2022 results presentation
Oslo, Norway, 26 August 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's first-half year...
Year: 2022
Philips spotlights integrated, data-driven cardiology solutions at ESC 2022
Clinicians using Ultrasound Workspace A clinician using Ultrasound Workspace Philips SmartSpeed MR software image August 26, 2022 Philips AI-powered interventional...
Mendus AB: Mendus AB (publ) interim report April – June 2022
Progress made throughout the second quarter puts the company in a strong position to deliver meaningful clinical progress in the...
Disclosure of received notification from The Goldman Sachs Group, Inc. and NN Group N.V.
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 26 August 2022 – 8AM CET Disclosure of received notification from The Goldman Sachs Group,...
Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022
REGULATED INFORMATION Preliminary documents for the Extraordinary General Meeting have been made available on company’s website Mont-Saint-Guibert, Belgium, 26 August 2022,...
IBA qualifies as the only supplier for second round of tender to provide ten proton therapy units across Spain
Louvain-La-Neuve, Belgium, 26 August, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s...
Mendus AB: Mendus announces financing commitments totaling up to SEK 250 million with Van Herk Investments and Negma Group
Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company addressing tumor recurrence through cell-based immunotherapies, today announces that it has entered...
Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)
-- the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDASHANGHAI, China, Aug. 25,...
Blueberries Medical Reports 2022 Q2 Financial Results and Provides Corporate and Operations Update
TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of...
Atrion Corporation Announces CFO Succession Plan
ALLEN, Texas, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Atrion Corporation. (NASDAQ: ATRI) today announced that its Board of Directors has...
Bicycle Health and Evernorth Team Up to Expand Access to Virtual Opioid Use Disorder Treatment
BOSTON, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bicycle Health today announced that its high-quality, evidence-based virtual opioid use disorder (OUD)...
Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors
Deals position Optimi Life nutraceutical brand for international distribution Optimi Life Optimi Life Bundle Optimi Life Optimi Life Optimi Life...
Cannabix Technologies Correlates THC in Breath and Blood using Proprietary Sample Collection and Analysis Hardware in Southern US Study
Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety Cannabix August...
Sofwave™ to Showcase SUPERB™ (Synchronous Ultrasound Parallel Beam Technology) Live and In-Person at 5CC International Aesthetic Medical and Dermatology Conference
Sofwave to host showcase booth from September 1-4Facial and neck treatment workshop held on September 2SUPERB neck, skin, and eyebrow...
WIMI Hologram Academy: The Application of AR Technology in Sports
HONG KONG, Aug. 25, 2022 (GLOBE NEWSWIRE) -- WIMI Hologram Academy, working in partnership with the Holographic Science Innovation Center,...
R1 RCM Announces 10-Year End-to-End Revenue Cycle Management Partnership with St. Clair Health
MURRAY, Utah, Aug. 25, 2022 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), announced today a 10-year partnership with...
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on...
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker
Issued claims will protect use of a biomarker to assess response to Lomecel-B™ in patients with blood vessel dysfunctionMIAMI, Aug....
Catalyst Biosciences, Inc. Declares Special Cash Dividend of $1.43 per share
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) (“Catalyst,” the “Company” or “we”)...
Anthos Therapeutics Launches Second Phase 3 Clinical Trial of Its Dual-acting Factor XI Inhibitor, Abelacimab
Abelacimab is the only Factor XI inhibitor currently being evaluated in Phase 3 trials The MAGNOLIA study will compare abelacimab...